India, April 22 -- Amid the ongoing tariff issues, Swiss drug major Roche Holding AG announced its plan to invest $50 billion in the United States in the next five years, aiming to expand its Pharmaceutical and Diagnostics Divisions. With all new and expanded manufacturing capacity, Roche aims to export more medicines from the US than it imports.
In a statement, the company said its diagnostics division already has an export surplus from the US to other countries.
Roche's latest investment includes new state-of-the art research and development or R&D sites, as well as new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California. An additional site location that will be announced soon.
The investment is...